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Introduction
Systemic lupus erythematosus (SLE) is a heterogeneous
autoimmune disease characterized by chronic inflamma-
tion that potentially leads to organ damage. Severe mani-
festations make the management of SLE difficult and
challenging. Nonsteroidal antiinflammatory drugs
(NSAIDs), antimalarial drugs, glucocorticoids, immuno-
suppressive and citotoxic agents are the mainstays of treat-
ment. Unfortunately, these agents are related to a vast
toxicity. For an amount of patients, these approaches arent
enough to achieve disease activity control, especially in
those with cytopenia, nephritis and neuropsychiatric
lupus. For these cases, Rituximab (RTX) – a chimeric
mouse/human monoclonal antibody specific for human
CD20 B-cell – has been widely prescribed. It is known
that B-cells have a central role in SLE pathogenesis, being
precursors of plasma cells production autoantibodies, pre-
cipitating inflammation by producing cytokines, activation
T-cells by presentation of self-antigens, and regulating
T-cells activity via co-stimulatory molecules. Although the
clinical trials of RTX in SLE had controversial results,
RTX seems to be a valuable option as an off-label drug for
refractory patients.
Objectives
To report the experience of a tertiary pediatric rheuma-
tology center with RTX for patients with refractory SLE.
Methods
We performed a retrospective chart review of patients
with SLE that received RTX in some moment of their dis-
ease from September 2009 to February 2013 due to refrac-
tory to traditional therapies. A satisfactory response was
defined as reaching SLEDAI reduction in at least 50%,
urina protein:creatinine ratio (UPCR) <50 mg/mmol
(equivalent to proteinuria <0.5g/24h), and corticoid taper-
ing to at least 50% of inicial dose.
Results
Seven patients were in use of the medication in the revised
period. All of then were female. Six patients had the diag-
nosis of lupus nephritis, and 1 had refractory plaquetope-
nia to standart drugs. Two patients had an inadequate
response to RTX. One of them persisted with refractory
plaquetopenia and the other died due to complications
related to SLE. Out of the 6 patients with lupus nephritis,
4 (66%) achieved SLEDAI reduction of at least 50% after
4-6 months of RTX, as well showed an important reduc-
tion of proteinuria (<0.5g/24h) and corticoid tapering.
One patient had improvement of her disease, however
without achieving the paramethers of satisfactory response
to the RTX. For this reason, this patient was considered to
have a partial response to the RTX. The results are
according to those found in similar studies.
Conclusion
It is suggested that RTX continues to be used as a thera-
peutic option for patients with refractory SLE or with con-
traindication to traditional drugs. Prospected studies are
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